An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products

International Journal of Risk and Safety in Medicine

Volumn 23, Issue 2, 2011, Pages 125-132

  Nielsen, Margrethe ^a   Gøtzsche, Peter ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Benzodiazepines; DDD; indications; sales; SSRIs

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DENMARK; DRUG MARKETING; PRESCRIPTION; PRIMARY MEDICAL CARE;

ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; COMMERCE; DENMARK; DRUG PRESCRIPTIONS; DRUG UTILIZATION; ECONOMICS, PHARMACEUTICAL; HUMANS; INAPPROPRIATE PRESCRIBING; MARKETING; PRIMARY HEALTH CARE; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS;

EID: 80051964375     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-2011-0526     Document Type: Article

References (20)

1. E.H. Hansen and M. Gyldmark, Psykofarmaka forbruget. Fordeling og udvikling (Psychotropic drugs use. Distribution and development). København: Sundhedsstyrelsen, 1990.
2. E.H. Hansen, Sovemedicin og nervemedicin - brug - afhængighed - intervention (Hypnotics and tranquillisers - use - dependency - intervention). København: Sundhedsstyrelsens Lægemiddelafdeling, 1997.
3. Lægemiddelkataloget (Pharmaceutical catalogue) 1983-2008. København: Dansk Lægemiddelinformation. Infomatum A/S.
4. Forbruget af antidepressiva i Danmark i den primære sundhedssektor i perioden 1994-2003 (Use of antidepressants i Denmark in primary health sector in the period 1994-2003). København: Lægemiddelstyrelsen, 2004.
5. Forbrugsudvikling af benzodiazepiner i Danmark 1996-2003 (Usage of benzodiazepines development in Denmark 1996-2003). København: Lægemiddelstyrelsen, 2004.
6. OECD Health at a glance 2007 :OECD Indicators. OECD 2007.
7. E.H. Turner, A.M. Matthews, E. Linardatos, R.A. Tell and R. Rosenthal, Selective publication of antidepressant trials and its influence on apparent efficacy, N Engl J Med 358 (2008), 252-260.
8. J.C. Fournier, R.J. DeRbeis, S.D. Hollon, S. Dimidjian, J.D. Amsterdam, R.C. Shelton and J. Fawcett, Antideressant drug effects and depression severity. A patient-level meta-analysis, JAMA 303 (2010), 47-53.
9. WHO Collaborating Centre for Drug Statistics methodology. [Online]. [Cited 2008 July 08. Available from: Http://www.whocc.no/atcddd/.
10. Diagnostic and Statistical Manual of Mental Disorders. Fourth edition. DSM IV Washington DC: American Psychiatric Association, 1994.
11. C. Medawar and A. Hardon, Medicines Out of Control, Aksant Academic Publishers, Amsterdam, 2004.
12. J. Schramm, M. Andersen, K. Vach, J. Kragstrup, J.P. Kampmann and J. Søndergaard, Promotional methods used by representatives of drug companies: A prospective survey in general practice, Scand J Prim Health Care 25 (2007), 93-97.
13. R. Moynihan, I. Heath and D. Henry, Selling sickness: The pharmaceutical industry and disease mongering, BMJ 324 (2002), 886-890.
14. P. Berney, D. Halperin, R. Tango, I. Daeniker-Dayer and P. Schulz, A major change of prescribing pattern in absence of adequate evidence: Benzodiazepines versus newer antidepressants in anxiety disorders, Psychopharmacol Bull 41 (2008), 39-47.
15. Reference program for unipolar depression hos voksne (Referenceprogramme for unipolar depression in adults). København: Sundhedsstyrelsen, 2007.
16. Depression: Management of depression in primary and secondary care. National Institute for Clinical Excellence; London, 2007.
17. N.K. Choudhry, H.T. Stelfox and A.S. Detsky, Relationships between authors of clinical practice guidelines and the pharmaceutical industry, JAMA 287 (2002), 612-617.
18. Danish Medicines Agency [Online]. [Cited 2010 October 20]. Available from: Http://www.laegemiddelstyrelsen.dk/ include/8806/tilladelse-laeger.asp
19. C. Lane, How Normal Behaviour Became a Sickness, Shyness, Yale University Press, New Haven and London, 2007.
20. L. Cosgrove, S. Krimsky, M. Vijayaraghavan and L. Schneider, Financial ties between DSM-IV panel members and the pharmaceutical industry, Psychother Psychosom 75 (2006), 154-160.